Vanucizumab clinical trials
Also written RO5520985.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses vanucizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vanucizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT02665416Written as Vanucizumab
- A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal CancerTerminatedPhase 2Hoffmann-La RocheNCT02141295Written as Vanucizumab
- A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT01688206Written as Vanucizumab
Codes
What other systems call vanucizumab · ClinicalTrials.gg INT000680
- MeSH (NLM) C000619444vanucizumabOne source NLM
- UNII (FDA) B800Z06O8KVANUCIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q25326698VanucizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C118578VanucizumabOne source FDA
- DrugBank DB12317One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000619444 | vanucizumab | One source NLM |
| UNII (FDA) | B800Z06O8K | VANUCIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q25326698 | Vanucizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C118578 | Vanucizumab | One source FDA |
| DrugBank | DB12317 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.